Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660801 | 0.89 | HTT (0.44) | KMT2AUSP2HTTKDM4EPOLB | |
| SCHEMBL11904081 | 0.86 | TP53 (0.40) | KMT2AUSP2HTTALPLKDM4E | |
| SCHEMBL12731289 | 0.84 | CRHR1 (0.39) | KDM4ETP53CRHR1ALDH1A1CYP3A4 | |
| SCHEMBL12731292 | 0.84 | CRHR1 (0.40) | KDM4ETP53CRHR1ALDH1A1CYP3A4 | |
| SCHEMBL1659936 | 0.82 | CRHR1 (0.37) | KMT2AUSP2HTTALPLMPO | |
| SCHEMBL12789052 | 0.79 | ADORA3 (0.36) | KMT2AKDM4EMEN1MPOADORA3 | |
| SCHEMBL11920576 | 0.78 | CRHR1 (0.36) | TP53CRHR1ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL1661747 | 0.75 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL12731288 | 0.72 | TSHR (0.39) | KMT2AUSP2HTTKDM4EMPO | |
| SCHEMBL1662822 | 0.72 | CRHR1 (0.61) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2487177-A1 | PYRAZOLOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487177-A1 | PYRAZOLOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20110086898-A1 | PYRAZOLOOXAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086898-A1 | PYRAZOLOOXAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086898-A1 | PYRAZOLOOXAZOLE COMPOUND | CRHR1, MC2R, CRHR2 | KMT2A 4639/4885USP2 4388/4885HTT 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.